{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:25:09Z","timestamp":1793082309556,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T00:00:00Z","timestamp":1749340800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T00:00:00Z","timestamp":1749340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s40123-025-01170-7","type":"journal-article","created":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T11:02:08Z","timestamp":1749380528000},"page":"2043-2053","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Use of a Viscous Cysteamine Eyedrop in a Belgian Cohort: Early 3-Year Results"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3389-8999","authenticated-orcid":false,"given":"Emiel","family":"Matthys","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7972-0139","authenticated-orcid":false,"given":"Heleen","family":"Delbeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0826-3879","authenticated-orcid":false,"given":"Karel","family":"Van Keer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2335-1845","authenticated-orcid":false,"given":"Ingele","family":"Casteels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,8]]},"reference":[{"issue":"1","key":"1170_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-016-0426-y","volume":"11","author":"MA Elmonem","year":"2016","unstructured":"Elmonem MA, Veys KR, Soliman NA, Van Dyck M, Van Den Heuvel LP, Levtchenko E. Cystinosis: a review. Orphanet J Rare Dis. 2016;11(1):1\u201317.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"1170_CR2","first-page":"94","volume":"2","author":"M Al-Haggar","year":"2013","unstructured":"Al-Haggar M. Cystinosis as a lysosomal storage disease with multiple mutant alleles: phenotypic-genotypic correlations. World J Nephrol. 2013;2(4):94\u2013102.","journal-title":"World J Nephrol"},{"key":"1170_CR3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/ndt\/gfu090","volume":"29","author":"F Emma","year":"2014","unstructured":"Emma F, Nesterova G, Langman C, Labb\u00e9 A, Cherqui S, Goodyer P, et al. Nephropathic cystinosis: an international consensus document. Nephrol Dial Transplant. 2014;29:87\u201394.","journal-title":"Nephrol Dial Transplant"},{"key":"1170_CR4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/ki.2011.277","volume":"81","author":"A Brodin-sartorius","year":"2012","unstructured":"Brodin-sartorius A, T\u00eate MJ, Niaudet P, Antignac C, Guest G, Ottolenghi C, et al. Cysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adults. Kidney Int. 2012;81:179\u201389.","journal-title":"Kidney Int"},{"key":"1170_CR5","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.2147\/OPTH.S36626","volume":"8","author":"F Shams","year":"2014","unstructured":"Shams F, Livingstone I, Oladiwura D, Ramaesh K. Treatment of corneal cystine crystal accumulation in patients with cystinosis. Clin Ophthalmol. 2014;8:2077\u201384.","journal-title":"Clin Ophthalmol"},{"issue":"4","key":"1170_CR6","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s40123-019-00216-x","volume":"8","author":"F Peeters","year":"2019","unstructured":"Peeters F, Cassiman C, Van Keer K, Levtchenko E, Veys K, Casteels I. Ophthalmic outcome in a belgian cohort of cystinosis patients treated with a compounded preparation of cysteamine eye drops: retrospective analysis. Ophthalmol Ther. 2019;8(4):623\u201333.","journal-title":"Ophthalmol Ther"},{"issue":"4","key":"1170_CR7","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1586\/17469899.2013.814885","volume":"8","author":"N Huynh","year":"2013","unstructured":"Huynh N, Gahl WA, Bishop RJ. Cysteamine ophthalmic solution 0.44% for the treatment of corneal cystine crystals in cystinosis. Expert Rev Ophthalmol. 2013;8(4):341\u20135.","journal-title":"Expert Rev Ophthalmol."},{"key":"1170_CR8","first-page":"47","volume":"42","author":"A Reda","year":"2018","unstructured":"Reda A, Van Schepdael A, Adams E, Paul P, Devolder D, Elmonem MA, et al. Effect of storage conditions on stability of ophthalmological compounded cysteamine eye drops. JIMD Rep. 2018;42:47\u201351.","journal-title":"JIMD Rep"},{"key":"1170_CR9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s40123-018-0156-4","volume":"8","author":"S Biswas","year":"2019","unstructured":"Biswas S, Sornalingam K. The ocular status of cystinosis patients receiving a hospital pharmacy-made preparation of cysteamine eye drops: a case series. Ophthalmol Ther. 2019;8:125\u201336.","journal-title":"Ophthalmol Ther"},{"key":"1170_CR10","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1136\/bjophthalmol-2016-309278","volume":"101","author":"A Al-Hemidan","year":"2017","unstructured":"Al-Hemidan A, Shoughy SS, Kozak I, Tabbara KF. Efficacy of topical cysteamine in nephropathic cystinosis. Br J Ophthalmol. 2017;101:1234\u20137.","journal-title":"Br J Ophthalmol"},{"key":"1170_CR11","unstructured":"European Medicines Agency. Cystadrops [Internet]. 2021 [cited 2024 Jun 15]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cystadrops#news-on"},{"issue":"4","key":"1170_CR12","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1167\/iovs.16-21080","volume":"58","author":"H Liang","year":"2017","unstructured":"Liang H, Labb\u00e9 A, Le MJ, Plisson C, Baudouin C. A new viscous cysteamine eye drops treatment for ophthalmic cystinosis: an open-label randomized comparative phase III pivotal study. Invest Ophthalmol Vis Sci. 2017;58(4):2275\u201383.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1170_CR13","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/ICO.0000000000003161","volume":"42","author":"S Biswas","year":"2023","unstructured":"Biswas S, Alzahrani K, Radhakrishnan H. Corneal densitometry to assess the corneal cystine deposits in patients with cystinosis. Cornea. 2023;42:313\u20139.","journal-title":"Cornea"},{"issue":"5","key":"1170_CR14","doi-asserted-by":"publisher","first-page":"3218","DOI":"10.1167\/iovs.15-16499","volume":"56","author":"H Liang","year":"2015","unstructured":"Liang H, Baudouin C, Tahiri Joutei Hassani R, Baudouin FB, Labbe A. Photophobia and corneal crystal density in nephropathic cystinosis: an in vivo confocal microscopy and anterior-segment optical coherence tomography study. Invest Ophthalmol Vis Sci. 2015;56(5):3218\u201325.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"1170_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s40123-017-0089-3","volume":"6","author":"AM Pinxten","year":"2017","unstructured":"Pinxten AM, Hua MT, Simpson J, Hohenfellner K, Levtchenko E, Casteels I. Clinical practice: a proposed standardized ophthalmological assessment for patients with cystinosis. Ophthalmol Ther. 2017;6(1):93\u2013104.","journal-title":"Ophthalmol Ther"},{"key":"1170_CR16","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1006\/mgme.2000.3062","volume":"71","author":"WA Gahl","year":"2000","unstructured":"Gahl WA, Kuehl EM, Iwata F, Lindblad A, Kaiser-Kupfer MI. Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eyedrops. Mol Genet Metab. 2000;71:100\u201320.","journal-title":"Mol Genet Metab"},{"key":"1170_CR17","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2147\/OPTH.S133516","volume":"12","author":"AK Makuloluwa","year":"2018","unstructured":"Makuloluwa AK, Shams F. Cysteamine hydrochloride eye drop solution for the treatment of corneal cystine crystal deposits in patients with cystinosis: an evidence-based review. Clin Ophthalmol. 2018;12:227\u201336.","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"1170_CR18","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s40123-018-0146-6","volume":"7","author":"S Biswas","year":"2018","unstructured":"Biswas S, Gaviria M, Malheiro L, Marques JP, Giordano V, Liang H. Latest clinical approaches in the ocular management of cystinosis: a review of current practice and opinion from the ophthalmology cystinosis forum. Ophthalmol Ther. 2018;7(2):307\u201322.","journal-title":"Ophthalmol Ther"},{"key":"1170_CR19","unstructured":"EMA Committee for Medicinal Products for Human Use (CHMP). Cystadrops assessment report [Internet]. Vol. 43. 2017. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cystadrops"},{"key":"1170_CR20","unstructured":"Michailidou A, Trenz HJ, de Wilde P. Cystadrops: summary of product characteristics. The internet and European integration. 2019."}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01170-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-025-01170-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01170-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T19:36:16Z","timestamp":1757187376000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-025-01170-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,8]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1170"],"URL":"https:\/\/doi.org\/10.1007\/s40123-025-01170-7","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,8]]},"assertion":[{"value":"12 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Emiel Matthys, Karel Van Keer, and Ingele Casteels have received speaker honorarium from Recordati Rare Diseases. Heleen Delbeke has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was acquired from the Ethics Committee of the University Hospital Leuven (study number S69355). Patients were informed about the study, and the study was performed in accordance with the Declaration of Helsinki of 1964 and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}